Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antisense Bcl-xL oligodeoxynucleotide
- Development stage
- Preclinical
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Subcutaneous, Parenteral
01
Overview
Antisense Bcl-xL oligodeoxynucleotide (ODN) is an experimental, research-stage antisense oligonucleotide therapeutic designed to target and suppress the expression of Bcl-xL (BCL2L1), an anti-apoptotic protein of the Bcl-2 family. By binding to Bcl-xL mRNA, this single-stranded DNA molecule induces sequence-specific downregulation of Bcl-xL protein expression, thereby restoring apoptotic sensitivity in cancer cells. It has been widely investigated in preclinical models of various malignancies, including prostate cancer, breast carcinoma, colorectal carcinoma, lung carcinoma, melanoma, and leukemia, often in combination with chemotherapeutic agents such as paclitaxel, doxorubicin, and cisplatin to overcome drug resistance.
- Other names
- antisense BCL-XL oligodeoxynucleotideantisense BCL-XL oligonucleotideantisense Bcl-xL ODN
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on antisense Bcl-xL oligodeoxynucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antisense Bcl-xL oligodeoxynucleotide.